Alto Neuroscience (ANRO) announced that the FDA has granted fast track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia. There are currently no approved treatments for CIAS, a core feature of schizophrenia that severely impacts daily functioning and quality of life for millions of patients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience initiated with a Buy at Chardan
- Innovative Biomarker Strategy and Promising Pipeline Drive Buy Rating for Alto Neuroscience
- Innovative Precision Psychiatry and Strong Financials Justify Buy Rating for Alto Neuroscience
- Alto Neuroscience announces results from replication study
- Promising Pipeline and Expert Backing Drive Buy Rating for Alto Neuroscience, Inc.